Management of patients with NTM-LD: Improving adherence for optimal outcomes

Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health or touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health or touchIME activities*
- *USF Health and touchIME accept no responsibility for errors or omissions*

A conversation between:

Prof. Doreen Addrizzo-Harris
NYU Grossman School of Medicine,
New York, NY, USA

Dr Ashwin Basavaraj
NYU Grossman School of Medicine,
New York, NY, USA

touch™ INFECTIOUS DISEASES

Approaches to reduce time to diagnosis and initiation of guideline-based treatment

Dr Ashwin Basavaraj

NYU Grossman School of Medicine
New York, NY, USA

Clinical presentation of NTM-LD

What is NTM-LD?

NTM-LD is the most common clinical manifestation of NTM infection and can lead to chronic, debilitating disease. Up to **85%** of NTM-LD cases are caused by **MAC.**[1]

Risk factors

- **Environmental**[2,3] (water, soil, dust)
- **Host**[2,3] (structural lung diseases, e.g. bronchiectasis, COPD)
- **Genetic**[3] (e.g. AATD, CF, PCD)
- **Immunologic**[2] (e.g. HIV, immunosuppressant exposure, including biologics and corticosteroids)
- **Host-susceptible phenotype**[4] (e.g. tall slender body habitus, pectus excavatum)



Symptoms[1,3]

- Cough
- Dyspnoea
- Excessive mucus production
- Fatigue
- Fever
- Haemoptysis
- Night sweats
- Weight loss

AATD, alpha-1-antitrypsin deficiency; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; MAC, *Mycobacterium avium* complex; NTM, nontuberculous mycobacteria; NTM-LD, NTM-lung disease; PCD, primary ciliary dyskinesia.

1. van Ingen J, et al. *Expert Rev Respir Med*. 2021;15:1387–401; 2. Feng J-Y, et al. *J Formos Med Assoc*. 2020;119(Suppl. 1):S23-31; 3. Pathak K, et al. *Int J Gen Med*. 2022;15:7619–29; 4. Sexton P, Harrison AC. *Eur Respir J*. 2008;31:1322–33.

touch™ INFECTIOUS DISEASES

Challenges associated with NTM-LD

1 Increasing prevalence and incidence in the USA[1]



2 Diagnostic challenges[2]

Diagnosis is challenging due **to non-specific symptoms** and **overlapping features** with other lung diseases, e.g. bronchiectasis and COPD

It can take up to **20 months** from initial clinical presentation to diagnosis

3 Burden of disease[3]

Delays in diagnosis may lead to:

- Worsening symptoms
- Decrease in social and physical functioning
- Decline in mental health
- Inappropriate management of the disease

COPD, chronic obstructive pulmonary disease; NTM-LD, nontuberculous mycobacterial lung disease.

1. Winthrop KL, et al. *Ann Am Thorac Soc*. 2020;17:178–85; 2. Ali J. *Expert Rev Respir Med*. 2021;15:663–73; 3. van Ingen J, et al. *Expert Rev Respir Med*. 2021;15:1387–401.

Diagnostic criteria for NTM-LD



- Pulmonary or systemic symptoms
- Exclusion of other diagnoses

- Nodular or cavitary opacities on chest radiograph, or bronchiectasis with multiple small nodules on chest HRCT scan

- Positive culture results from ≥2 separate expectorated sputum samples
  OR
- Positive culture result from ≥1 bronchial wash or lavage **OR**
- Transbronchial/lung biopsy with mycobacterial histologic features and positive NTM culture from biopsy or ≥1 sputum/bronchial wash

HRCT, high-resolution computed tomography; NTM, nontuberculous mycobacteria; NTM-LD, NTM-lung disease.

Daley CL, et al. *Eur Respir J*. 2020;56:2000535.

The setting of individualized treatment goals in collaboration with patients

Dr Ashwin Basavaraj

NYU Grossman School of Medicine
New York, NY, USA

Recommended treatment regimens for macrolide-susceptible MAC NTM-LD

Disease type	Drug regimen	Dosing frequency
Nodular-bronchiectatic	**Three-drug macrolide-based regimen:** Azithromycin, in preference to clarithromycin Rifamycin (rifampin or rifabutin) Ethambutol	**TIW or QD** (based on severity) **for ≥12 months** after culture conversion
Cavitary	**Three-drug macrolide-based regimen** **+/- amikacin IV* (streptomycin)**	**QD for ≥12 months** after culture conversion **TIW for aminoglycosides**
Refractory†	**Three-drug macrolide-based regimen** **+ ALIS‡ OR amikacin IV* (streptomycin)**	**QD** **TIW for aminoglycosides**

*Consider for cavitary, extensive nodular-bronchiectatic disease or macrolide-resistant MAC in the initial treatment regimen; †Defined as remaining sputum culture-positive after 6 months of guideline-based therapy; ‡ALIS has been shown to improve culture conversion when added to guideline-based therapy in treatment-refractory patients with MAC pulmonary disease.
ALIS, amikacin liposome inhalation suspension; IV, intravenous; MAC, *Mycobacterium avium* complex; NTM-LD, nontuberculous mycobacterial lung disease; QD, once daily; TIW, three times a week.

Daley CL, et al. *Eur Respir J*. 2020;56:2000535.

Alternative treatments for MAC NTM-LD

Drug (off-label use)	Dose and frequency	Monitoring
Clofazimine*[1,2]	100–200 mg QD	Clinical monitoring; liver function; ECG (QTc)
Bedaquiline†[3]	Weeks 1–2: 400 mg QD Weeks 3–24: 200 mg TIW	Clinical monitoring; liver function; ECG (QTc)
Linezolid[1,4]	600 mg QD	Clinical monitoring; visual acuity/colour discrimination; CBC
Tedizolid[5]	200 mg QD	Clinical monitoring; CBC
Inhaled amikacin parenteral formulation (when ALIS not available)[1]	250–500 mg QD	Renal, auditory and vestibular toxicity

*An investigational new drug application is required for clofazimine in the USA; †Approved for multidrug-resistant tuberculosis.
ALIS, amikacin liposome inhalation suspension; CBC, complete blood count; ECG, electrocardiogram; MAC, *Mycobacterium avium* complex; NTM-LD, nontuberculous mycobacterial lung disease; TIW, three times a week; QD, once daily; QTc, corrected QT interval.

1. Daley CL, et al. *Eur Respir J*. 2020;56:2000535; 2. FDA. Clofazimine PI. Available at: https://bit.ly/3WGdHWD (accessed 8 November 2022); 3. FDA. Bedaquiline PI. Available at: https://bit.ly/3UlgVwV (accessed 8 November 2022); 4. FDA. Linezolid PI. Available at: https://bit.ly/3SliEuL (accessed 8 November 2022); 5. FDA. Tedizolid PI. Available at: https://bit.ly/3DO52Zh (accessed 8 November 2022).

touch™ INFECTIOUS DISEASES

Improving efficacy and decreasing drug-related toxicity

Dr Ashwin Basavaraj

NYU Grossman School of Medicine
New York, NY, USA

Key adverse reactions to antimicrobial therapy for NTM-LD

Drug	Adverse reactions
ALIS	• Cough • Dysphonia • Dyspnoea • Nephrotoxicity • Ototoxicity • Vestibular toxicity
Amikacin, streptomycin, tobramycin	• Electrolyte disturbance • Nephrotoxicity • Ototoxicity • Vestibular toxicity
Ethambutol	• Neuropathy • Ocular toxicity
Macrolides (azithromycin and clarithromycin)	• Gastrointestinal • Hepatotoxicity • Prolonged QTc • Tinnitus/hearing loss
Rifamycin (rifampin or rifabutin)	• Cytopenia • Hepatotoxicity • Hypersensitivity • Orange discolouration of secretions

Clinical monitoring*

*Monitoring frequency should be individualized based on treatment regimen, age, comorbidities, concurrent drugs, overlapping drug toxicities and resources.
ALIS, amikacin liposome inhalation suspension; NTM-LD, nontuberculous mycobacterial lung disease; QTc, corrected QT interval.
Daley CL, et al. *Eur Respir J.* 2020;56:2000535.

touch™ INFECTIOUS DISEASES

Real-world treatment outcomes in NTM-LD (USA)

Clinical outcomes in patients undergoing macrolide/azalide therapy for nodular/bronchiectatic MAC-LD

Retrospective single-centre review of patients (N=180) completing >12 months of macrolide/azalide multidrug therapy

- Sputum conversion to negative in **86%** of patients
- Treatment success* in **84%** of patients
- **No patients** developed treatment resistance

Treatment regimen modification occurred more frequently with daily vs intermittent therapy **(80% vs 1%; p=0.0001)**

9% of treatment episodes discontinued prior to 12 months of planned treatment due to medication intolerance; **1%** due to macrolide/azalide intolerance

*Sputum conversion without true microbiologic relapse with the original infecting MAC genotype.
MAC-LD, *Mycobacterium avium* complex lung disease; NTM-LD, nontuberculous mycobacterial lung disease.
Wallace RJ, et al. *Chest*. 2014;146:276–82.

touch™ INFECTIOUS DISEASES

Real-world treatment outcomes in NTM-LD (Europe)

Clinical outcomes in patients undergoing multidrug antibiotic therapy for NTM-LD at a TB reference centre[1]

Observational, retrospective study of patients (N=170) at a median follow-up of 31 months

- Side effects occurred in **37.6%** of patients
- Treatment failure* in **4.1%** of patients
- Treatment discontinued in **13.5%** of patients

Median time to treatment discontinuation due to side effects was **234 days** after treatment initiation

The main reason for discontinuation of treatment was **drug intolerance**

*Defined as re-emergence of multiple positive cultures or persistence of positive cultures with the causative species from respiratory samples after ≥12 months of antimycobacterial treatment, while still on treatment.[2]

NTM-LD, nontuberculous mycobacterial lung disease; TB, tuberculosis.

1. Aliberti S, et al. *Respir Med*. 2020;164:105899; 2. van Ingen J, et al. *Eur Respir J*. 2018;51:1800170.